Andrys C, Borska L, Pohl D, Fiala Z, Hamakova K, Krejsek J
Department of Clinical Immunology and Allergy, School of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic.
Arch Dermatol Res. 2007 Mar;298(10):479-83. doi: 10.1007/s00403-006-0723-8.
Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Goeckerman's therapy is still the first line therapy of psoriasis in the Czech Republic because of its low cost and long-term efficacy. Disturbances in angiogenic activity are characteristic for the immunopathogenesis of psoriasis. An abnormal spectrum of cytokines, growth factors and proangiogenic mediators is produced by keratinocytes and inflammatory cells in patients suffering from the disease. The aim of this study was to evaluate the influence of GT of psoriasis on angiogenic activities by comparing serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 44 patients with psoriasis in peripheral blood samples collected before and after therapy. Forty otherwise healthy blood donors serve as a control group. The efficacy of GT was delineated by psoriasis area and severity index (PASI). The disease activity was significantly diminished by GT (P < 0.001). The serum levels of both VEGF and bFGF were statistically significantly correlated to PASI value in patients before the treatment by GT. The serum levels of VEGF (329.4 +/- 125.5 microg/ml) and bFGF (10.2 +/- 5.04 pg/ml) in patients before GT were significantly higher than those measured in healthy blood donors (VEGF 236.4 +/- 55.9 pg/ml, bFGF 7.3 +/- 3.7 pg/ ml). The serum levels of both VEGF and bFGF were significantly diminished by GT. The level of VEGF dropped from 329.4 +/- 125.5 pg/ml before GT to 278.5 +/- 109.9 pg/ml after GT (P = 0.0042) and the level of bFGF fell from 10.2 +/- 5.04 to 7.78 +/- 4.5 pg/ml (P = 0.019). Comparing to healthy controls, the serum level of bFGF in psoriasis patients was normalised (P = 0.5723) after GT. In contrast, the serum level of VEGF remained significantly increased in psoriasis patients after GT in comparison with healthy blood donors (P = 0.0319). In conclusion, we found that the angiogenic potential which is abnormally increased in patients with psoriasis is significantly alleviated by GT.
戈克曼疗法(GT)治疗银屑病的方法是每天在患部皮肤涂抹药用级煤焦油,随后进行紫外线照射。由于成本低且疗效持久,戈克曼疗法仍是捷克共和国治疗银屑病的一线疗法。血管生成活性紊乱是银屑病免疫发病机制的特征。银屑病患者的角质形成细胞和炎性细胞会产生异常的细胞因子、生长因子和促血管生成介质谱。本研究的目的是通过比较44例银屑病患者治疗前后外周血样本中血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)的血清水平,评估GT对银屑病血管生成活性的影响。40名其他方面健康的献血者作为对照组。GT的疗效通过银屑病面积和严重程度指数(PASI)来描述。GT显著降低了疾病活动度(P < 0.001)。在GT治疗前,患者血清中VEGF和bFGF的水平与PASI值均存在显著的统计学相关性。GT治疗前患者血清中VEGF(329.4 +/- 125.5微克/毫升)和bFGF(10.2 +/- 5.04皮克/毫升)的水平显著高于健康献血者(VEGF 236.4 +/- 55.9皮克/毫升,bFGF 7.3 +/- 3.7皮克/毫升)。GT显著降低了血清中VEGF和bFGF的水平。VEGF水平从GT治疗前的329.4 +/- 125.5皮克/毫升降至GT治疗后的278.5 +/- 109.9皮克/毫升(P = 0.0042),bFGF水平从10.2 +/- 5.04降至7.78 +/- 4.5皮克/毫升(P = 0.019)。与健康对照组相比,GT治疗后银屑病患者血清中bFGF水平恢复正常(P = 0.5723)。相反,与健康献血者相比,GT治疗后银屑病患者血清中VEGF水平仍显著升高(P = 0.0319)。总之,我们发现银屑病患者异常升高的血管生成潜能通过GT得到了显著缓解。